This article summarizes available data for the use of CYP3A4 inhibitors with midostaurin for acute myeloid leukemia.
Danielle Schlafer, PharmD, BCOP
Advertisement
Articles by Danielle Schlafer, PharmD, BCOP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Relacorilant Combo in Platinum-Resistant Ovarian Cancers
2
Navigating New Horizons in Neuroendocrine Prostate Cancer
3
FDA Clears Investigator-Initiated IND for SRN-101 in Recurrent High-Grade Glioma
4
The Intersection of Technology and Psycho-Oncology Care
5